MX343580B - Anticuerpos contra el g-csfr y sus usos. - Google Patents

Anticuerpos contra el g-csfr y sus usos.

Info

Publication number
MX343580B
MX343580B MX2013014711A MX2013014711A MX343580B MX 343580 B MX343580 B MX 343580B MX 2013014711 A MX2013014711 A MX 2013014711A MX 2013014711 A MX2013014711 A MX 2013014711A MX 343580 B MX343580 B MX 343580B
Authority
MX
Mexico
Prior art keywords
csfr
antibodies against
antibodies
bind
present disclosure
Prior art date
Application number
MX2013014711A
Other languages
English (en)
Other versions
MX2013014711A (es
Inventor
Donald Nash Andrew
Elizabeth Andrews Arna
Mae Edwards Kirsten
Philip Hardy Matthew
Panousis Con
Dunlop Felicity
Baca Manuel
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47353852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX343580(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of MX2013014711A publication Critical patent/MX2013014711A/es
Publication of MX343580B publication Critical patent/MX343580B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a proteínas que comprenden dominios de unión a antígenos de anticuerpos que se unen al receptor del factor estimulador de colonias de granulocitos humano.
MX2013014711A 2011-06-13 2012-06-13 Anticuerpos contra el g-csfr y sus usos. MX343580B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496351P 2011-06-13 2011-06-13
PCT/AU2012/000675 WO2012171057A1 (en) 2011-06-13 2012-06-13 Antibodies against g-csfr and uses thereof

Publications (2)

Publication Number Publication Date
MX2013014711A MX2013014711A (es) 2014-09-01
MX343580B true MX343580B (es) 2016-11-10

Family

ID=47353852

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014711A MX343580B (es) 2011-06-13 2012-06-13 Anticuerpos contra el g-csfr y sus usos.

Country Status (14)

Country Link
US (5) US9193793B2 (es)
EP (1) EP2718326B1 (es)
JP (1) JP6187777B2 (es)
KR (1) KR101822702B1 (es)
CN (1) CN103649123B (es)
AU (1) AU2012269720B2 (es)
CA (1) CA2838246C (es)
DK (1) DK2718326T3 (es)
ES (1) ES2828482T3 (es)
IL (1) IL229468B (es)
MX (1) MX343580B (es)
RU (1) RU2605595C2 (es)
SG (1) SG195043A1 (es)
WO (1) WO2012171057A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3280441T3 (da) 2015-04-07 2021-11-15 Alector Llc Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
WO2019075053A1 (en) * 2017-10-11 2019-04-18 Elanco Us Inc. PORCINE G-CSF VARIANTS AND USES THEREOF
ES2939461T3 (es) 2017-11-29 2023-04-24 Csl Ltd Método para tratar o prevenir la lesión por isquemia-reperfusión
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
KR20210100638A (ko) * 2018-12-04 2021-08-17 씨에스엘 이노베이션 피티와이 엘티디 호중구 질환을 치료하는 방법
BR112021024788A2 (pt) * 2019-06-12 2022-04-19 CSL Innovation Pty Ltd Conjugados de variante de receptor de complemento solúvel tipo 1 e usos dos mesmos
WO2021068074A1 (en) * 2019-10-08 2021-04-15 Zymeworks Inc. Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same
AU2021285088A1 (en) * 2020-06-04 2023-01-05 CSL Innovation Pty Ltd Method of treating or preventing acute respiratory distress syndrome

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5844094A (en) 1992-09-25 1998-12-01 Commonwealth Scientific And Industrial Research Organization Target binding polypeptide
AUPM375194A0 (en) 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
JP2000319298A (ja) 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
WO2004108158A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-cd3 antibody
DK2330121T3 (en) 2004-06-02 2014-12-15 Adalta Pty Ltd Binding moieties based on shark IgNar domains
WO2006033386A1 (ja) 2004-09-22 2006-03-30 Kirin Beer Kabushiki Kaisha 安定化されたヒトIgG4抗体
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
US7871979B2 (en) * 2006-07-06 2011-01-18 Merck Serono Sa CSF3R polypeptides and uses thereof
JP5235881B2 (ja) * 2006-08-11 2013-07-10 シーエスエル、リミテッド 肺疾患病態の処理
AU2009335798B2 (en) 2008-12-19 2014-11-27 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2010206681A1 (en) 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
KR101750426B1 (ko) 2009-09-15 2017-06-23 씨에스엘 리미티드 신경 질환들의 치료
US8968731B2 (en) 2009-10-09 2015-03-03 Csl Limited Treatment of uveitis

Also Published As

Publication number Publication date
US20120321630A1 (en) 2012-12-20
RU2605595C2 (ru) 2016-12-20
RU2014100642A (ru) 2015-07-20
US20170226214A1 (en) 2017-08-10
US20210009701A1 (en) 2021-01-14
MX2013014711A (es) 2014-09-01
EP2718326B1 (en) 2020-08-19
US20160031998A1 (en) 2016-02-04
JP2014519517A (ja) 2014-08-14
DK2718326T3 (da) 2020-10-26
CN103649123B (zh) 2017-05-24
US20190055313A1 (en) 2019-02-21
WO2012171057A1 (en) 2012-12-20
AU2012269720A1 (en) 2013-03-21
CN103649123A (zh) 2014-03-19
NZ617725A (en) 2015-02-27
IL229468B (en) 2021-05-31
AU2012269720B2 (en) 2015-01-22
ES2828482T3 (es) 2021-05-26
BR112013031943A2 (pt) 2016-11-22
KR20140041717A (ko) 2014-04-04
IL229468A0 (en) 2014-01-30
US9193793B2 (en) 2015-11-24
EP2718326A1 (en) 2014-04-16
CA2838246A1 (en) 2012-12-20
EP2718326A4 (en) 2015-07-08
SG195043A1 (en) 2013-12-30
CA2838246C (en) 2018-07-10
JP6187777B2 (ja) 2017-08-30
KR101822702B1 (ko) 2018-01-26

Similar Documents

Publication Publication Date Title
MX343580B (es) Anticuerpos contra el g-csfr y sus usos.
EP4219552A3 (en) Il-11r binding proteins and uses thereof
PH12014502527B1 (en) St2 antigen binding proteins
MX343659B (es) Proteínas de unión receptoras fc.
MX2020011064A (es) Inmunoglobulinas heterodimericas.
MY160590A (en) Cd127 binding proteins
IN2014CN03042A (es)
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
NZ626610A (en) Antibodies that bind csf1r
EA201400579A1 (ru) Антитела к il-36r
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
MX358367B (es) Anticuerpos para el receptor de la barrera hematoencefálica de baja afinidad y sus usos.
WO2012006341A3 (en) Anti-ron antibodies
MX2014004326A (es) Anticuerpos a cd1d.
DK2623592T3 (da) Anti-humane ccr7-antistoffer, hybridom, medicinsk sammensætning og antistof-immobiliseret bærer
MX2013002960A (es) Composiciones de anticuerpo y metodos de uso.
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
UA110051C2 (uk) Антитіло, яке зв'язує tgf-альфа та епірегулін
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.
EP2886556A4 (en) MONOCLONAL ANTIBODY WHICH BINDERS SPECIFICALLY TO THE TM4SF5 PROTEIN AND USE THEREOF
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
NZ757754A (en) Antibodies that bind csf1r
NZ621320A (en) Anti-human xcr1 antibodies

Legal Events

Date Code Title Description
FG Grant or registration